News and analysis on the global poultry
and animal feed industries.
on March 1, 2012

Harrisvaccines to provide process development for vaccine project

Harrisvaccines has been named to provide RNA process development for a trivalent vaccine against the hemorrhagic fever-causing filoviruses known as Ebola virus and Marburg virus.

The project is funded by a $15 million contract overseen by the Chemical Biological Medical Systems-Joint Vaccine Acquisition Program, which are responsible for developing, acquiring and stockpiling Food and Drug Administration-approved vaccines to protect against biological weapons. The filovirus project marks Harrisvaccines’ first foray into human vaccines.

Comments powered by Disqus